JWM Grindelwald 30-01-2008 Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands Johan W. Mouton Pharmacodynamic Indices.

Slides:



Advertisements
Similar presentations
Monte Carlo simulations and bioequivalence of antimicrobial drugs NATIONAL VETERINARY S C H O O L T O U L O U S E July 2005 Didier Concordet.
Advertisements

A 23 Variability in the Size of the Fluoroquinolone AUC/MIC for Antibacterial Effect in S.aureus: Impact for Clinical Breakpoints A. R. Noel, K.E. Bowker,
Pharmacodynamics of MASKO Compounds (Macrolides, Azalides, Streptogramins, Ketolides, and Oxazolidinones) William A. Craig, MD University of Wisconsin.
Animal Model PK/PD: A Tool for Drug Development
Pharmacodynamics and the Dosing of Antibacterials
Eccmid 2003 Aminoglycosiden bij neonaten Canisius-Wilhelmina Hospital Nijmegen, The Netherlands Johan W Mouton Relationship between bacterial killing,
Augmentin® ES Clinical Microbiology Review
Plasmids Chromosome Plasmid Plasmid + Transposon Plasmid + integron Plasmid+transposon +intergron Chromosome Chromosome + transposon Chromosome + transposon.
Michael R. Jacobs, MD, PhD Professor of Pathology and Medicine Case Western Reserve University Director of Clinical Microbiology University Hospitals of.
Overview of Use of PK-PD in Streamlining Drug Development William A. Craig Professor of Medicine University of Wisconsin.
Pharmacodynamics of Antibiotics
The (important) role of the pharmacist in the handling of COPD - H. Lode - Free University Berlin.
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.
WHICH PK-PD MEASURE FOR WHICH DRUG? Sujata M. Bhavnani, Pharm.D, MS Institute for Clinical Pharmacodynamics Ordway Research Institute Latham, New York.
Gokaraju Rangaraju College of Pharmacy
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 In Vitro/Animal Models to Support Dosage Selection: FDA Perspective.
PK/PD of Antibiotics in relation to resistance Otto Cars MD Department of Medical Sciences Infectious diseases Uppsala University Sweden.
Synergism : what does it mean? JW Mouton Dept Medical Microbiology Canisius Wilhelmina Hospital Nijmegen, The Netherlands.
The General Concepts of Pharmacokinetics and Pharmacodynamics Hartmut Derendorf, PhD University of Florida.
Rational Dosing: The Use of Plasma Concentrations vs. Tissue Concentrations Hartmut Derendorf, PhD University of Florida.
Application of PK/PD modeling for optimization of linezolid therapy Julia Zayezdnaya Zack.
8th ISAP Symposium Can PK/PD be used in everyday clinical practice? Francesco Scaglione Department of Pharmacology, Toxicology and Chemotherapy, University.
Pharmacodynamics of Antimicrobials in Animal Models William A. Craig, M.D. University of Wisconsin-Madison.
FADDI RAJESH V. DUDHANI, JIAN LI, ROGER L. NATION Facility for Anti-infective Drug Development & Innovation Drug Delivery,
EMEA London Pharmacokinetic- pharmacodynamic integration in veterinary drug development: an overview P.L. Toutain National Veterinary School ;Toulouse.
PK/PD - ICC - Manila, June 5th, The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place ? Paul.
Use of in vitro models to study the emergence of resistance Professor Inga Odenholt Department of Infectious Diseases University hospital, Malmö Sweden.
William A. Craig Symposium ISAP Research Meeting PK/PD and Genomics David Andes University of Wisconsin.
A Pharmacodynamic Model for Cefprozil against Haemphilus influenzae in an in vitro Infection Model across Multiple Regimens Olanrewaju O. Okusanya, Pharm.D,
PK/PD of Antibiotics in relation to resistance Otto Cars MD Department of Medical Sciences Infectious diseases Uppsala University Sweden.
Preclinical Models to Support Dosage Selection
Pharmacokinetics of Antimicrobials in Animals: Lessons Learned William A. Craig, M.D. University of Wisconsin-Madison.
Population PK-PD Modeling of Anti-Infective Agents
The Endpoint from a Resistance Point of View A Symposium to Honor the Career of William A. Craig, M.D. George Drusano, M.D. Co-Director Ordway Research.
Multiple dosing: intravenous bolus administration
Ten Years After: Where is ISAP?
Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein.
Issues in testing regimens containing multiple novel agents I. Preclinical Testing Jacques Grosset Johns Hopkins University School of Medicine, Baltimore,
Pharmacodynamics of Antifungals
The Rational Use of Antibiotics
Pharmacodynamics of Antimicrobials in Animal Models William A. Craig, M.D. University of Wisconsin-Madison.
1 Developments in pK/pD: optimising efficacy & prevention of resistance A critical review of pK/pD in in vitro models Alasdair MacGowan Bristol Centre.
BIOPHARMACEUTICS.
1 Motivation and philosophy for development of mechanistic PK/PD models in infectious diseases William A. Craig Symposium October 29 th 2008 University.
Antibiotic Resistance Emerging antibiotic resistance is a major health concern. 2 million people in the U.S. infected with antibiotic resistant bacteria.
Pharmacodynamic Indices Canisius-Wilhelmina Hospital Nijmegen, The Netherlands Johan W Mouton.
Pk/Pd modelling : Clinical Implications
PK/PD: TOWARDS DEFINITIVE CRITERIA PK/PD in clinical Practice: new level of PK/PD Francesco Scaglione Department of Pharmacology, Toxicology and Chemotherapy,
Lecture 2 Clearance, maintenance dose and AUC
The General Concepts of Pharmacokinetics and Pharmacodynamics
Improvement in Dose Selection Through Clinical PK/PD in Antimicrobial Drug Development: Perspective of an Industry PK/PD Scientist Gregory A. Winchell,
Pharmacodynamics of Antimicrobials William A. Craig, M.D. University of Wisconsin-Madison.
Source: Frank M. Balis Concentration and Effect vs. Time Conc./ Amount Effect [% of E MAX ] Time Central Compartment Peripheral Compartment Effect Compartment.
MACROLIDES: pharmacokinetics and pharmacodynamics
Table 3 Clinical response success rate, according to prior effective antimicrobial therapy in hospitalized patients with community-acquired pneumonia given.
International Society for Anti-infective Pharmacology (ISAP)
Temocillin pharmacokinetics in healthy volunteers
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place ? Paul M. Tulkens Cellular and Molecular.
Evaluation of the Efficacy of Intramuscular (IM) Administration of Ceftaroline (CPT) Against a Methicillin-Resistant Staphylococcus aureus (MRSA) Strain.
Oral session: PK/PD-based optimized broad-spectrum beta-lactam therapy (Sunday 10 April, 11:30) Achieving pharmacokinetic/pharmacodynamic (PK/PD) targets.
Optimizing Aminoglycoside Use
Doripenem vs Meropenem: a summary of International and Belgian published data Françoise Van Bambeke, Unité de Pharmacologie cellulaire et moléculaire Louvain.
P.L. Toutain VMAS symposium/workshop Uppsala 13 December 2017
Françoise Van Bambeke, Dr Sc. Pharm, Agr. Ens. Sup.
Antibiotic Resistance Emerging antibiotic resistance is a major health concern. 2 million people in the U.S. infected with antibiotic resistant bacteria.
Pharmacokinetics and pharmacodynamics of fluoroquinolones
Pharmacodynamic indices in targeting therapy of critical infections
M.R. Jacobs  Clinical Microbiology and Infection 
The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach  J.W. Mouton, D.F.J. Brown, P. Apfalter, R. Cantón,
Presentation transcript:

JWM Grindelwald Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands Johan W. Mouton Pharmacodynamic Indices

JWM Grindelwald Dosing should be such that the level of antmicrobial activity is associated with a high likelihood of therapeutic success.

JWM Grindelwald Dose Finding - The Past

JWM Grindelwald How can PK/PD help here? Potency of a drug (MIC) Exposure to the bug In vivo (PK) Efficacy of the drug

JWM Grindelwald Lowest concentration with no visible growth after 18 hour incubation MIC MIC = 2 mg/L X-acin 500 mg PK

JWM Grindelwald Pharmacokinetic Parameter (and Dose) MIC Thus, we have to: –Establish a relationship between the MIC in vitro and concentrations in vivo (thus, dosing regimens) –Determine which dosing regimens are optimal for Treatment in relation to the MIC

JWM Grindelwald Any idea where we are today? No idea… may be a mouse? Might be a human, though…

JWM Grindelwald PK/PD Neutropenic mouse thigh model Various doses and dosing regimens (q1 to q24) Outcome parameter: cfu counts after 24 h Plot PD parameter (AUC, Peak T>MIC) to effect

JWM Grindelwald K. pneumoniae, imipenem Based on data from Craig

JWM Grindelwald For K.pneumoniae, there is no clear relation between total daily dose of imipenem and efficacy in an in vivo model of infection

JWM Grindelwald K. pneumoniae, imipenem Based on data from Craig

JWM Grindelwald For beta-lactams, there is a direct relation between Time > MIC and efficacy

JWM Grindelwald Relationship between T>MIC, Peak, AUC and effect of levofloxacin for S. pneumoniae in mice. Each dot represents one mouse / dosingregimen. Based on data from Scaglione & Mouton, 2001, 2003

JWM Grindelwald levofloxacin ceftazidime Andes IJAA 2002 PK/PD relationship is Class Dependent

JWM Grindelwald T>MICAUC PenicillinsAminoglycosides CephalosporinsFluoroquinolones CarbapenemsMetronidazole MonobactamsLipopeptides TribactamsKetolides Macrolides Clindamycin Streptogramins GlycopeptidesGlycylcyclines Oxazolidinones Tetracyclines Azoles Relationship PkPd and Effect

JWM Grindelwald Relationship AUC and effect What has the MIC to do with this? Scaglione et al., AAC 2003

JWM Grindelwald Andes et al ISHAM 2003 Fluconazole efficacy in mice Dose vs MIC

JWM Grindelwald MIC PEAK AUC T > MIC AUC and Peak are usually linearly related to Dose Pharmacokinetic parameters : Measures of Exposure

JWM Grindelwald Pharmacodynamic index (AUC/MIC, Peak/MIC, T>MIC) Pharmacokinetic parameter MIC 'Normalizing pk/pd relationships'

JWM Grindelwald Andes et al ISHAM 2003

JWM Grindelwald In vitro effect at fixed concentrations In vivo CT profile dynamic concentrations MIC Response Curve

JWM Grindelwald Rodriguez-Tudela et al, AAC 2007 Fluconazole efficacy, OPC N=123

JWM Grindelwald Thus, 2 factors influence the value of the pk/pd index: MIC and its Errors/variation Pharmacokinetics and its variation

JWM Grindelwald Why is the term pk/pd index used instead of pk/pd parameter? -a ratio (e.g.) of two independent parameters, not a parameter by itself Mouton et al, J Antmicrob Chemother Available from ISAP site

JWM Grindelwald The MIC

JWM Grindelwald The MIC is a result of : kill over time (kill rate) by the antibiotic growth over time (growth rate) for a certain number of micro-organisms (the inoculum) MIC AT STATIC CONCENTRATIONS

JWM Grindelwald Kahlmeter et al, JAC 2003

JWM Grindelwald Growth and/or kill rate dependent : –strain, species –medium composition, brand –MH, supplements, ISO –number of bacteria –inoculum – (CLSI) vs 10 5 (BSAC) –temperature (35 o vs 37 o ) –growth phase –CO 2 –etc.

JWM Grindelwald Mouton, icaac 2000

JWM Grindelwald A reference MIC method has been described by ISO/CEN Accepted by member States, pending final vote ALL METHODS USED UN THE FUTURE SHOULD BE VALIDATED AGAINST THIS METHOD The method complies with CLSI and EUCAST Several Posters at this ECCMID

JWM Grindelwald The reproducibility of the MIC is within 2 2-fold dilutions. The variation introduced in the AUC/MIC and Peak/MIC values by the MIC is there for at least 0.5 tot 2 x the pk/pd index value!

JWM Grindelwald SC= The concentration of antimicrobial at which growth equals kill, i.e. no net growth or kill at a certain point in time =NOT equal to MIC (which includes time) Distinguish between MIC in vitro and in vivo. Mouton & Vinks Clin Pharmacokinet : MIC vs SC (Stationary Concentration)

JWM Grindelwald MIC MISCONCEPTION: 'Drug is active for a prolonged period of time, and remains above the MIC long enough to…. The SC may be lower or higher than the MIC, depending on its kill kinetics In general the SC is lower, especially for concentration dependent drugs Mouton & Vinks Clin Pharmacokinet :201-10

JWM Grindelwald PHARMACOKINETIC parameters

JWM Grindelwald Definition :The Area under the Concentration-time curve over 24 hours. Note: ….. It should be stated how the AUC is determined : based on (log) linear trapezoideal rule, based on clearance, or based on microconstants. Dimensions : concentration x time e.g. mg.h/L or  g.h /mL Mouton et al, J Antmicrob Chemother Available from ISAP site AUC

JWM Grindelwald AUC 0-24 = 3033 AUC inf = 5100 AUC 0-24 sd = 1361 AUC inf sd =1700 Mg.h/L

JWM Grindelwald WHICH AUC? AUC 0-24h or AUC  Steady State? (log) trapezodeal rule? Derived ? (A/  +B/  or other)

JWM Grindelwald Definition : The area under the concentration-time curve over 24 hours in steady state divided by the MIC. …. Note : ….For unbound fraction of the drug, use fAUC/MIC Dimensions : no dimensions Mouton et al, J Antmicrob Chemother 2005 Available from ISAP site AUC/MIC

JWM Grindelwald Definition :The Area under the inhibitory curve over 24 hours. Note: the AUIC should be reserved for those cases where actual inhibitory titers have been measured and used in the calculations. The AUIC is not equal to the AUC/MIC. See also Flaherty et al, AAC 1988;32(12): ; Hyatt JM et al AAC 1994;38(12):2730-7; Occhipinti DJ et al, AAC 1997;41(11): Dimensions : none AUIC Mouton et al, J Antmicrob Chemother 2005 Available from ISAP site

JWM Grindelwald Peak/MIC Definition : the peak level divided by the MIC. Dimensions : no dimensions. Mouton et al, J Antmicrob Chemother 2005 Available from ISAP site

JWM Grindelwald Scaglione et al, AAC 2003 WHICH PEAK LEVEL? After the 1st, 2nd or later dose? If more than one compartment, the peak level in compartment 1, 2 or even 3?

JWM Grindelwald Scaglione et al, AAC 2003

JWM Grindelwald Time > MIC Definition : the % of time above the MIC over a period of 24 hours. Note : if the period is other than 24 h, this should be stated explicitly. Dimensions : %. Mouton et al, J Antmicrob Chemother 2005 Available from ISAP site

JWM Grindelwald Variation in methods, definitions Variation in estimation Variation in population

JWM Grindelwald For all indices : how are they determined how are they calculated what is the error? Only when these questions have been answered do we know the true impact and value of the index.